VidPrevtyn Beta is a recombinant, adjuvanted DNA vaccine given as a booster dose to prevent COVID-19. It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the fall armyworm,...
- Mechanism
- Curator reviewed · 5 references
The antigenic component of VidPrevtyn Beta is a soluble trimeric SARS-CoV-2 recombinant spike protein (B.1.351 strain) stabilized in its prefusion conformation and deleted of its transmembrane and intracellular domains. It is combined with an adjuvant, AS03, that serves to enhance the immune response. Administered intramuscularly, VidPrevtyn Beta elicits an active immune response that provides protection against COVID-19 caused by SARS-CoV-2.
- Primary indication
- VidPrevtyn Beta is indicated as a booster dose to prevent COVID-19 in adults who have previously received an mRNA or adenoviral vector COVID-19 vaccine.Curator reviewed · 1 structured indication
- Code names
- SP-0253
What you can answer from here — as of March 06, 2025
Which other approved drugs treat the same conditions as VidPrevtyn Beta, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account